- Home
- AMRN vs SLGL Comparison
AMRN vs SLGL Comparison
Compare AMRN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | SLGL |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 276.9M |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AMRN | SLGL |
|---|---|---|
| Price | $14.08 | $78.14 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 45.8K | 41.1K |
| Earning Date | 04-29-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $181,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.22 | N/A |
| 52 Week Low | $12.96 | $20.06 |
| 52 Week High | $20.90 | $97.97 |
Technical Indicators
Market Signals| Indicator | AMRN | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 51.35 |
| Support Level | $14.02 | $67.89 |
| Resistance Level | $14.55 | $93.74 |
| Average True Range (ATR) | 0.34 | 6.12 |
| MACD | 0.04 | -0.63 |
| Stochastic Oscillator | 40.62 | 55.61 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.